Okay, search for "ATL-B4" "MK-5180", you will find some Koren article, stating ALT-B4 is MK-5180.
Translate this page "Jan 5, 2023 — Alteogen has a platform, ALT-B4, that converts injectable biopharmaceuticals into subcutaneous formulations. ... MK-5180 was assumed to be ALT-B4. The need for MK-5180 this year..."
Translate this page "Jan 5, 2023 — MK-5180 assumed to be ALT-B4. The need for MK-5180 is expected to be revealed in the first half of this year. Both general subcutaneous formulation clinical trials were completed in February this year..."
Translate this page "Aug 25, 2021 — Hyundai Motor Securities announced on the 25th that Alteogen's subcutaneous injection (SC) formulation change technology, 'human hyaluronidase (ALT-B4)... (pembrolizumab formulated with MK-5180), will be administered subcutaneously. (SC) Injection..."
Translate this page "The Keytruda SC formulation, which is believed to have incorporated Alteogen technology, is currently in phase 1 clinical trials under the name ‘MK-5180’. According to the global clinical trial site ClinicalTrials, the MK-5180 clinical trial will investigate the pharmacokinetics of the Keytruda SC formulation in 72 patients with advanced and metastatic solid tumors. The clinical trial ends on September 18th of this year."
News 
Market Data 
Discover 
